NEWS: Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation
Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation 03 February 2017 New guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) advises that all hepatitis C patients should be screened for hepatitis B before starting treatment with new Direct-acting Antivirals (DAAs). If patients are infected with both viruses this does not preclude treatment but this should be […]
Read more